Clinical trials in progressive neurological diseases

Frontiers of Neurology and Neuroscience

Volumn 25, Issue , 2009, Pages 144-151

  Bedlack, Richard S ^a   Cudkowicz, Merit E ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; MINOCYCLINE; PLACEBO; RILUZOLE; TOPIRAMATE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CANCER PATIENT; CHELATION THERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; DIAGNOSTIC TEST; DOCTOR PATIENT RELATION; FOLLOW UP; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; HUNTINGTON CHOREA; METABOLOMICS; METHODOLOGY; MITOCHONDRIAL MYOPATHY; MULTIPLE SCLEROSIS; MUSCULAR DYSTROPHY; NEUROLOGIC DISEASE; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIMARY LATERAL SCLEROSIS; PRIORITY JOURNAL; PROTEOMICS; REGISTER; RESPIRATORY DISTRESS SYNDROME; REVIEW; SAMPLE SIZE; SPINAL MUSCULAR ATROPHY; SPINOCEREBELLAR DEGENERATION; TRACHEOSTOMY; ARTICLE; DISEASE COURSE; PATIENT SELECTION;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; NERVOUS SYSTEM DISEASES; PATIENT COMPLIANCE; PATIENT SELECTION;

EID: 67649826881     PISSN: 16604431     EISSN: 16622804     Source Type: Book Series    
DOI: 10.1159/000209493     Document Type: Review

References (32)

1. Miller RG, Rosenberg JA, Gelinas DF, et al: Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review), report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999;52:1311-1323.
2. Bensimon G, Lacomblez L, Meininger V: A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
3. Lacomblez L, Bensimon G, Leigh P, et al: Dose ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
4. Bedlack RS, Traynor BJ, Cudkowicz ME: Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotrophic lateral sclerosis. Expert Opin Emerg Drugs 2007;12:229-252.
5. Davis S, Wright P W, Schulman SF, et al: Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with non-participants. Cancer 1985;56:1710-1718.
6. Reiser J, Warner JO: The value of participating in an asthma trial. Lancet 1985;206-207.
7. Croteau H, Brisson N, Lemaire J, Latreille J: The benefit of participating to clinical research. Breast Cancer Res Treat 2005;91:279-281.
8. Househam E, Swash M: Diagnostic delay in amyotrophic lateral sclerosis: what scope for improvement? J Neurol Sci 2000;180:76-81.
9. Pasinetti G, Ungar L, Lange J, et al: Identification of potential CSF biomarkers in ALS. Neurology 2006; 66:1218-1222.
10. Johnson CA, Stanton BR, Turner MR, et al: Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city london. J Neurol 2006;253:1642-1643.
11. Kasarkis E, Dominick K, Oddone E: The National Registry of Veterans with Amyotrophic Lateral Sclerosis: Department of Veterans Affairs Cooperative Studies Program (CSP) #500a. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(suppl 1):129-132.
12. Van Den Berg JP, Kalmijn S, Lindeman E, et al: Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 2005;65:1264-1267.
13. Traynor BJ, Codd MB, Corr B, Forde C, Frost BA, Hardiman O: Incidence and prevalence of ALS in Ireland, 1995-1997. Neurology 1999;52:504.
14. Cudkowicz M, Shefner J, Schoenfeld D, et al: A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61: 456-464.
15. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H, Neville HE, Boylan K, Mozaffar T, Belsh JM, Ravits J, Bedlack RS, Graves MC, McCluskey LF, Barohn RJ, Tandan R; Western ALS Study Group: Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007;6: 1045-1053.
16. American Medical Association Council on Scientific Affairs: Visibility and cancer clinical research: patient accrual, coverage, and reimbursement. J Natl Cancer Inst 1991;83:254-259.
17. To improve clinical trials participation, groups plan an awareness campaign. Cancer Lett 2000;26:1-3.
18. Executive Summary. Summit IV: Improving Communication and Public Awareness, October 4-6, 2000. http://www.cancersummit.org/summit-meetings/ summit-IV-summary.pdf (accessed July 21, 2007).
19. Ellis P: Attitudes toward participation in randomized clinical trials in oncology: a review of the literature. Ann Oncol 1999;11:939-945.
20. Comis RL, Aldigé CR, Stovall EL, et al: A quantitative survey of public attitudes towards cancer clinical trials. Philadelphia, Coalition of National Cancer Cooperative Groups, Cancer Research Foundation of America, Cancer Leadership Council and Oncology Nursing Society, 2000. http://www.cancertrialshelp.org/CTHpd/308-9.pdf (accessed July 21, 2007).
21. Lara PN Jr, Higdon R, Lim N, et al: Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001;19:1728-1733.
22. Grossman SA, Piantadosi S, Covahey C: Are informed consent forms that describe clinical oncology research protocols readable by most patients and their families? J Clin Oncol 1994;12:2211-2215.
23. Daugherty CK, Lyman K, Mick R, et al: Differences in perceptions of goals, expectations, and level of informed consent in phase I clinical trials. Proc Am Soc Clin Oncol 1996;15:352a.
24. Daugherty CK, Kialbasa TA, Siegler M, et al: Informed consent in clinical research: A study of cancer patient understanding of consent forms and alternatives of care in phase I clinical trials. Proc Am Soc Clin Oncol 1997;16:188a.
25. Simes RJ, Tattersall MHN, Coates AS, et al: Randomized comparison of procedures for obtaining informed consent in clinical trials of cancer. BMH 1986;293:1065-1068.
26. Aaronson NK, Visser-Pol E, Leenhousts GHMW, et al: Telephone-based nursing intervention improves the effectiveness of the informed consent process in cancer clinical trials. J Clin Oncol 1996;14:984-996.
27. Kaufmann P, Levy G, Montes J, et al: Excellent interrater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotroph Lateral Scler 2007;8:42-46.
28. Tansey C, Matte A, Needham D, Herridge M: Review of retention strategies in longitudinal studies and application to follow up of ICU survivors. Intensive Care Med 2007;33:2051-2057.
29. Twitchell GR, Hertzog CA, Klein JL, Schuckit MA: The anatomy of a follow up. Br J Addict 1992;87: 1327-1333.
30. Pullar T, Kumar S, Feely M: Compliance in clinical trials. Ann Rheum Dis 1989;48:871-875.
31. Huang H, Maguire M, Miller E, Appel L: Impact of pill organizers and blister packs on adherence to pill taking in two vitamin supplementation trials. Am J Epidemiol 2000;152:780-787.
32. Oba K, Morita S, Mahbubur R, Sakamoto J: Factors associated with compliance and non-compliance by physicians in a large-scale randomized clinical trial. Trials 2006;7:26.